Plethico Pharmaceuticals Peer Comparison

NSE: PLETHICO | BSE: 532739

₹7.94

₹-0.41 (-4.91%)

As on 13-Jun-2016IST

Market cap

₹27 Cr

Revenue (TTM)

₹765 Cr

P/E Ratio

P/B Ratio

Div. Yield

0 %

Edit

	Plethico Pharmaceuticals	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Market cap (₹ Cr)	27	35,748	28,932	28,386	28,458
Revenue (₹ Cr)	765	3,564	1,936	1,462	9,205
Net Profit (₹ Cr)	-277.72	414.00	288.22	387.35	-371.81
Net Margin (%)	-36.30	11.23	14.79	26.01	-3.93
RoE (%)	-3.05	8.38	29.77	25.18	-3.85
Price to Earnings	--	87.40	100.38	73.50	--
Price-To-Book	0.02	7.10	21.55	16.45	3.55

Income Statement (₹ Cr)

	Plethico Pharmaceuticals	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Operating Revenue	1,631.54	4,350.50	34.80	33.90	--
Total Income	1,664.40	4,375.84	34.80	34.61	--
Total Expenditure	1,470.36	2,996.79	25.65	30.42	--
EBITDA	161.19	1,353.71	9.15	3.48	--
Depreciation	17.73	115.07	2.71	1.05	--
EBIT	143.46	1,238.64	6.44	2.42	--
Interest	67.04	269.02	2.51	1.10	--
Other Income	32.86	25.34	0.42	0.71	--
Exceptional Items	-63.00	-473.77	--	--	--
Profit before Tax	109.28	521.19	3.93	2.03	--
Provision for Tax	7.79	221.74	1.40	0.68	--
Profit after Tax	101.49	299.45	2.52	1.35	--

	Plethico Pharmaceuticals	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Shareholder's Funds	1,366.97	1,471.02	37.49	6.11	--
Minority Interest	--	--	--	--	--
Non-Current Liabilities	259.47	2,891.88	5.39	0.04	--
Current Liabilities	1,096.26	1,890.94	24.92	15.82	--
Total Liabilities	2,731.65	6,253.84	67.79	22.09	--

	Plethico Pharmaceuticals	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Non-Current Assets	1,021.84	3,772.33	47.64	5.51	--
Current Assets	1,700.86	2,481.51	20.15	16.45	--
Total Assets	2,731.65	6,253.84	67.79	22.09	--
Total Debt*	1,187.23	3,492.50	19.14	6.41	--
Net Current Assets	604.59	590.57	-4.76	0.63	--
Contingent Liabilities	234.37	46.91	0.71	--	--

	Plethico Pharmaceuticals	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Cash From Operating Activities	-61.01	1,343.83	5.07	--	--
Cash Flow from Investing Activities	7.52	-305.45	-4.60	--	--
Cash from Financing Activities	-40.51	-826.56	-0.83	--	--
Net Cash Inflow / Outflow	-94.00	211.82	-0.36	0.00	--

	Plethico Pharmaceuticals	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
ROCE (%)	7.07	16.20	12.09	25.61	--
ROE (%)	7.48	66.74	14.65	24.87	--
ROA (%)	3.85	4.97	4.06	6.42	--
EBIT Margin (%)	11.89	31.70	26.29	12.34	--
Net Margin (%)	6.10	6.84	7.25	3.90	--
Cash Profit Margin (%)	7.31	9.52	15.04	6.56	--

	Plethico Pharmaceuticals	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Revenue Growth (%)	5.17	15.97	65.29	21.86	--
EBIT Growth (%)	-35.45	29.05	42.04	27.63	--
Net Profit Growth (%)	-1.38	212.90	6.25	7.55	--
EPS Growth (%)	-1.38	278.36	6.25	7.55	--
Book Value Growth (%)	1.64	253.45	15.81	28.51	--

	Plethico Pharmaceuticals	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Price / Earnings	10.26	17.64	0.00	0.00	--
Price / Book Value	0.76	9.37	0.00	0.00	--
Dividend Yield (%)	0.00	0.00	--	--	--
EV/EBITDA	11.32	7.33	4.36	1.71	--
Market Cap (₹ Cr)	1,041.09	6,555.46	0.00	0.00	--

	Plethico Pharmaceuticals	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Debt to Equity	0.87	2.39	0.51	1.05	--
Short term debt to equity ratio	0.16	0.18	0.21	0.88	--
Current Ratio	1.55	1.31	0.81	1.04	--
Quick Ratio	1.38	0.84	0.77	0.66	--
Interest Coverage	2.63	2.94	2.57	2.86	--

	Plethico Pharmaceuticals	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Debtors to sales (%)	75.01	17.44	42.51	24.27	--
Asset Turnover	0.62	0.72	0.56	1.74	--
Receivable days	245.46	57.17	120.33	81.45	--
Inventory Days	41.56	67.16	9.04	45.36	--
Payable days	23.59	116.25	535.25	134.63	--
Cash Conversion Cycle	263.43	8.07	-393.94	-7.82	--

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.